Articles by : Rich Daly, Editor in Chief

Drugmaker Overcharge Fines for 340B Drugs Reach Nearly $7,000

October 11, 2023 Rich Daly, Editor in Chief Views

Drugmaker overcharge fines, which the Department of Health and Human Services assesses, recently increased to nearly $7,000.

The federal fine for each instance of drugmaker overcharges for 340B covered entities recently increased to nearly $7,000. The fine [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Two Drugmakers Post Refund Notices on HRSA Website

October 11, 2023 Rich Daly, Editor in Chief Views

Drugmakers Noven and Granules each owe refunds to 340B providers, according to notices posted on HRSA's Office of Pharmacy Affairs website.

Noven Pharmaceuticals and Granules Pharmaceuticals owe refunds to 340B providers, according to notices posted on the Health Resources and Services [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

As Medicare Lump Sum Payment Regulation Heads to Finish Line, Critics Weigh In

October 3, 2023 Rich Daly, Editor in Chief Views

In response to the ongoing Change Healthcare cyberattack, CMS will direct contractors to provide some accelerated payments to hospitals.

The final rule to provide repayment to many 340B hospitals for five years of unlawful Medicare cuts entered the final [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Health, Researchers Spar over Biosimilar Study

September 28, 2023 Rich Daly, Editor in Chief Views

Maureen Testoni, president and CEO of 340B Health, said she anticipates bipartisan legislation on drugmaker 340B contract pharmacy restrictions.

Researchers rejected criticism of a recent study in an academic journal they co-authored from the leader of a 340B hospital [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Transparency, Patient Assistance Requirements Needed in 340B, Say Drugmaker-Backed Groups

September 28, 2023 Rich Daly, Editor in Chief Views

Justin Leventhal, a senior policy analyst for the American Consumer Institute, has advocated for more 340B transparency alongside other drugmaker-backed groups.

Amid ongoing congressional legislative proposals to boost transparency and other requirements for 340B hospitals, two advocacy groups that receive drugmaker [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Hospital 340B Sites increased by 400% Over 11 Years, Analysis Finds

September 26, 2023 Rich Daly, Editor in Chief Views

A consulting firm analysis found that hospital 340B covered entity and child sites increased more than fourfold over the last 11 years.

Hospital 340B covered entity and child sites increased by more than 400% over the last 11 years, while the number [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Providers Try a Range of Responses to Manufacturer 340B Contract Pharmacy Restrictions

September 26, 2023 Rich Daly, Editor in Chief Views

Community health centers are attempting to mitigate the adverse financial effects of manufacturer 340B contract pharmacy restrictions on their organizations, said Colleen Meiman, national policy advisor for State & Regional Associations of Community Health Centers.

Amid an increasing number of drugmaker restrictions and requirements on the use of contract pharmacies, 340B providers are trying a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Incyte Becomes 26th Drugmaker to Place Contract Pharmacy Restrictions

September 21, 2023 Rich Daly, Editor in Chief Views

Incyte will no longer allow 340B hospitals to have direct delivery of Opzelura products purchased at the 340B discount price to contract pharmacies.

Drug manufacturer Incyte Corp. this week announced it will become the 26th drug manufacturer to restrict access to 340B pricing when [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

One Quarter of HRSA Provider Audits Closed with No Adverse Findings

September 21, 2023 Rich Daly, Editor in Chief Views

Dept. of Health and Human Services sign and building

There were no adverse findings in nearly one quarter of provider audits conducted by HRSA, an agency within HHS.

Nearly one-quarter of the 200 provider audits planned for this year were closed by regulators with no adverse findings, they [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

AHF Files Appeal Over Its Claim That Apexus Did Not Obtain Sub-Ceiling Discounts

September 19, 2023 Rich Daly, Editor in Chief Views

AHF appealed a ruling to dismiss by U.S. District Judge Percy Anderson over AHF's claim that Apexus did not obtain sub-ceiling discounts..

The AIDS Healthcare Foundation (AHF) recently filed an appeal to an April district court dismissal of its case against Apexus, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live